Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT

Although the newly developed second-generation anti-androgen drug enzalutamide can repress prostate cancer progression significantly, it only extends the survival of prostate cancer patients by 4–6 months mainly due to the occurrence of enzalutamide resistance. Most of the previous studies on AR ant...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cell Death Dis
Main Authors: Liu, Qiuli, Tong, Dali, Liu, Gaolei, Xu, Jing, Do, Khang, Geary, Kyla, Zhang, Dianzheng, Zhang, Jun, Zhang, Yao, Li, Yaoming, Bi, Gang, Lan, Weihua, Jiang, Jun
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2017
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5596596/
https://ncbi.nlm.nih.gov/pubmed/28837141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2017.417
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki